Poei Darin, Ali Sana, Ye Shirley, Hsu Robert
Department of Internal Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Cancer Drug Resist. 2024 May 23;7:20. doi: 10.20517/cdr.2024.25. eCollection 2024.
Anaplastic lymphoma kinase () gene rearrangements have been identified as potent oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC). The discovery of ALK inhibition using a tyrosine kinase inhibitor (TKI) has dramatically improved the outcomes of patients with ALK-mutated NSCLC. However, the emergence of intrinsic and acquired resistance inevitably occurs with ALK TKI use. This review describes the molecular mechanisms of ALK TKI resistance and discusses management strategies to overcome therapeutic resistance.
间变性淋巴瘤激酶（ALK）基因重排在包括非小细胞肺癌（NSCLC）在内的多种恶性肿瘤中已被确定为强大的致癌驱动因素。使用酪氨酸激酶抑制剂（TKI）抑制ALK的发现显著改善了ALK突变型NSCLC患者的治疗结果。然而，使用ALK TKI不可避免地会出现原发性和获得性耐药。本综述描述了ALK TKI耐药的分子机制，并讨论了克服治疗耐药的管理策略。
Zotero 插件